ABCL - Abcellera Biologics Inc

ABCL - Abcellera Biologics Inc

https://www.abcellera.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

AbCellera Biologics ( ABCL ) Q2 2025 Earnings Call Transcript

Motley Fool • 1 month, 1 week ago • score: 0.23

Image source: The Motley Fool.Thursday, August 7, 2025, at 5 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...

Strength Seen in ABCELLERA BIOLG ( ABCL ) : Can Its 15.0% Jump Turn into More Strength?

Zacks Commentary • 1 month, 3 weeks ago • score: 0.39

ABCELLERA BIOLG (ABCL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

Motley Fool • 3 months, 1 week ago • score: 0.35

Investors were surely discovering drug discovery company AbCellera Biologics ( NASDAQ: ABCL ) as the trading week kicked off on Monday. On encouraging news in an important North American jurisdiction, those folks bid the biotech's stock up by almost 6% on the day.

AbCellera Biologics Inc. ( ABCL ) Reports Q1 Loss, Misses Revenue Estimates

Zacks Commentary • 4 months ago • score: -0.03

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 11.76% and 49.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.

52W High

$5.82

52W Low

$1.89

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.65

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

27.47

EV/EBITDA (<8 favorable)

5.30

EV/Revenue (<3 favorable)

26.40

P/S (TTM) (<3 favorable)

38.90

P/B (<3 favorable)

1.27

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

22.94%

Institutions (25–75% balanced)

38.47%

Shares Outstanding

298,833,000

Float

202,749,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

32,876,000

Gross Profit (TTM)

-135,880,000

EPS (TTM)

-0.56

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-2.90%

ROE (TTM) (>15% strong)

-0.16%

EPS YoY (Quarterly) (>10% good)

0.46

Revenue YoY (Quarterly) (>8% good)

1.33

Momentum

Bearish momentum

Value

0.0266

Previous

0.0081

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025